These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 14757155

  • 1. Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences.
    Onoue S, Matsumoto A, Nagano Y, Ohshima K, Ohmori Y, Yamada S, Kimura R, Yajima T, Kashimoto K.
    Eur J Pharmacol; 2004 Feb 06; 485(1-3):307-16. PubMed ID: 14757155
    [Abstract] [Full Text] [Related]

  • 2. Structure-activity relationship of synthetic truncated analogues of vasoactive intestinal peptide (VIP): an enhancement in the activity by a substitution with arginine.
    Onoue S, Ohmori Y, Matsumoto A, Yamada S, Kimura R, Yajima T, Kashimoto K.
    Life Sci; 2004 Feb 06; 74(12):1465-77. PubMed ID: 14729396
    [Abstract] [Full Text] [Related]

  • 3. Structure-function studies of analogues of parathyroid hormone (PTH)-1-34 containing beta-amino acid residues in positions 11-13.
    Peggion E, Mammi S, Schievano E, Silvestri L, Schiebler L, Bisello A, Rosenblatt M, Chorev M.
    Biochemistry; 2002 Jun 25; 41(25):8162-75. PubMed ID: 12069609
    [Abstract] [Full Text] [Related]

  • 4. Antagonistic effect of a vasoactive intestinal peptide fragment, vasoactive intestinal peptide(1-11), on guinea pig trachea smooth muscle relaxation.
    Goossens JF, Pommery N, Lohez M, Pommery J, Helbecque N, Cotelle P, Lhermitte M, Henichart JP.
    Mol Pharmacol; 1992 Jan 25; 41(1):104-9. PubMed ID: 1732717
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Peptide-YY and neuropeptide-Y inhibit vasoactive intestinal peptide-stimulated adenosine 3',5'-monophosphate production in rat small intestine: structural requirements of peptides for interacting with peptide-YY-preferring receptors.
    Servin AL, Rouyer-Fessard C, Balasubramaniam A, Saint Pierre S, Laburthe M.
    Endocrinology; 1989 Feb 25; 124(2):692-700. PubMed ID: 2536315
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Solution structure of vasoactive intestinal polypeptide (11-28)-NH2, a fragment with analgesic properties.
    Haghjoo K, Cash PW, Farid RS, Komisaruk BR, Jordan F, Pochapsky SS.
    Pept Res; 1996 Feb 25; 9(6):327-31. PubMed ID: 9048428
    [Abstract] [Full Text] [Related]

  • 10. The C-terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin.
    Wulff B, Møller Knudsen S, Adelhorst K, Fahrenkrug J.
    FEBS Lett; 1997 Aug 25; 413(3):405-8. PubMed ID: 9303545
    [Abstract] [Full Text] [Related]

  • 11. Transglutaminase-mediated polyamination of vasoactive intestinal peptide (VIP) Gln16 residue modulates VIP/PACAP receptor activity.
    De Maria S, Metafora S, Metafora V, Morelli F, Robberecht P, Waelbroeck M, Stiuso P, De Rosa A, Cozzolino A, Esposito C, Facchiano A, Cartenì M.
    Eur J Biochem; 2002 Jul 25; 269(13):3211-9. PubMed ID: 12084061
    [Abstract] [Full Text] [Related]

  • 12. Association of vasoactive intestinal peptide with polymer-grafted liposomes: structural aspects for pulmonary delivery.
    Stark B, Debbage P, Andreae F, Mosgoeller W, Prassl R.
    Biochim Biophys Acta; 2007 Mar 25; 1768(3):705-14. PubMed ID: 17204237
    [Abstract] [Full Text] [Related]

  • 13. Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
    Dangoor D, Biondi B, Gobbo M, Vachutinski Y, Fridkin M, Gozes I, Rocchi R.
    J Pept Sci; 2008 Mar 25; 14(3):321-8. PubMed ID: 17924396
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
    Koerber SC, Gulyas J, Lahrichi SL, Corrigan A, Craig AG, Rivier C, Vale W, Rivier J.
    J Med Chem; 1998 Dec 03; 41(25):5002-11. PubMed ID: 9836618
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
    Gourlet P, Vandermeers A, Van Rampelbergh J, De Neef P, Cnudde J, Waelbroeck M, Robberecht P.
    Ann N Y Acad Sci; 1998 Dec 11; 865():247-52. PubMed ID: 9928018
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. 99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies.
    Pallela VR, Thakur ML, Chakder S, Rattan S.
    J Nucl Med; 1999 Feb 11; 40(2):352-60. PubMed ID: 10025846
    [Abstract] [Full Text] [Related]

  • 20. Respirable powder formulation of a shortened vasoactive intestinal peptide analog for treatment of airway inflammatory diseases.
    Suzuki H, Mizumoto T, Seto Y, Sato H, Onoue S.
    J Pept Sci; 2018 Mar 11; 24(3):. PubMed ID: 29441631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.